​

Funding Round

Venture Round - Neurovance

Venture Round - Neurovance

Investment Firm

Overview

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

Announced Date

Oct 18, 2012

Closed on Date

Oct 18, 2012

Funding Type

Series Unknown

Highlights

Location

United States, North America

Social

N/A

Investor Lead

Novartis Venture Fund

Novartis Venture Fund

Novartis Venture Fund is a early_stage_venture and late_stage_venture and post_ipo and seed firm.

Participant Investors

5

Investor Name
Participant InvestorTimothy J. Barberich
Participant InvestorTekla Capital Management
Participant InvestorState of Wisconsin Investment Board
Participant InvestorNovartis Venture Fund
Participant InvestorGBS Ventures

Round Details and Background

Neurovance raised $7000000 on 2012-10-18 in Venture Round

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

Company Funding History

6

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 26, 2015
Series A - Neurovance
-5.5M
Apr 03, 2014
Series A - Neurovance
7-6.3M
Oct 18, 2012
Venture Round - Neurovance
6-7.0M
Feb 03, 2012
Venture Round - Neurovance
-478.1K

Recent Activity

There is no recent news or activity for this profile.